Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ sulfamethizole (antibiotic)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antibacterial Action: Sulfamethizole belongs to the sulfonamide class of antibiotics, which work by inhibiting the growth and reproduction of bacteria. It achieves this by interfering with the synthesis of folic acid, a crucial component for bacterial growth. By blocking folic acid production, sulfamethizole effectively prevents the bacteria from multiplying and eventually leads to their death.

  2. Treatment of Urinary Tract Infections: Sulfamethizole is commonly prescribed to treat urinary tract infections (UTIs) caused by susceptible strains of bacteria, including Escherichia coli and other gram-negative organisms. UTIs can affect the bladder, urethra, or kidneys and may present with symptoms such as frequent urination, painful urination, and urinary urgency. Sulfamethizole helps eradicate the bacteria responsible for the infection, thereby alleviating symptoms and resolving the infection.

  3. Dosage and Administration: Sulfamethizole is typically administered orally in the form of tablets or capsules. The dosage and duration of treatment depend on factors such as the severity of the infection, the patient's age and weight, and the susceptibility of the causative bacteria. It is essential to follow the healthcare provider's instructions regarding dosage, administration, and duration of treatment to ensure effective therapy and minimize the risk of bacterial resistance.

  4. Adverse Effects: While sulfamethizole is generally well-tolerated, some individuals may experience adverse effects. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Allergic reactions or hypersensitivity responses, including skin rash, itching, and swelling, may occur in some individuals. In rare cases, severe allergic reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis may occur, necessitating immediate medical attention.

  5. Precautions and Considerations: Sulfamethizole should be used with caution in individuals with a history of allergies or hypersensitivity to sulfonamide antibiotics. Patients with renal impairment should be monitored closely during treatment, as sulfamethizole is primarily eliminated by the kidneys. Adequate hydration should be maintained to prevent crystalluria and kidney damage. It is essential to complete the full course of treatment as prescribed, even if symptoms improve before the medication is finished, to ensure eradication of the infection and prevent recurrence.

  6. Drug Interactions: Sulfamethizole may interact with other medications, including anticoagulants, oral hypoglycemic agents, and phenytoin, among others. It is essential to inform the healthcare provider about all medications, supplements, and herbal products being taken to avoid potential interactions or adverse effects.

  7. Resistance: Overuse or misuse of sulfamethizole can contribute to the development of bacterial resistance. Therefore, it is crucial to use sulfamethizole judiciously and only when indicated to preserve its effectiveness for the treatment of urinary tract infections and minimize the risk of bacterial resistance.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of sulfamethizole (antibiotic) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by sulfamethizole (antibiotic)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Odoribacter genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Ruminococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Bacteroides xylanisolvens species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Blautia obeum species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Bacteroides ovatus species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Ruminococcus bromii species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Veillonella parvula species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of sulfamethizole (antibiotic) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.4 -0.4
ADHD 3.3 0.4 7.25
Age-Related Macular Degeneration and Glaucoma 0.1 0.1
Allergic Rhinitis (Hay Fever) 0.3 1.9 -5.33
Allergies 2 1.9 0.05
Allergy to milk products 0.3 0.4 -0.33
Alopecia (Hair Loss) 0.2 0.2
Alzheimer's disease 2 1.8 0.11
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3 0.9 2.33
Ankylosing spondylitis 0.6 0.7 -0.17
Anorexia Nervosa 0.8 -0.8
Antiphospholipid syndrome (APS) 0.9 0.9
Asthma 1.1 1.6 -0.45
Atherosclerosis 0.6 1.4 -1.33
Atrial fibrillation 1.2 0.6 1
Autism 4.5 5.1 -0.13
Barrett esophagus cancer 0.1 0 0
Bipolar Disorder 0.3 0.5 -0.67
Brain Trauma 0.4 0.3 0.33
Carcinoma 1.7 1.4 0.21
Celiac Disease 0.8 2.7 -2.38
Cerebral Palsy 0.8 0.6 0.33
Chronic Fatigue Syndrome 3.4 2.1 0.62
Chronic Kidney Disease 0.7 0.3 1.33
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.3 -2
Chronic Urticaria (Hives) 0 1.2 0
Coagulation / Micro clot triggering bacteria 0 0.3 0
Colorectal Cancer 1.9 0.4 3.75
Constipation 0.6 0.2 2
Coronary artery disease 0.1 0.1 0
COVID-19 6.8 8 -0.18
Crohn's Disease 3.3 3.1 0.06
cystic fibrosis 0.7 -0.7
deep vein thrombosis 0.2 -0.2
Depression 7.4 2.8 1.64
Dermatomyositis 0 0.4 0
Eczema 0 0.8 0
Endometriosis 0.9 0.8 0.13
Eosinophilic Esophagitis 0.1 0 0
Epilepsy 1.7 2 -0.18
Fibromyalgia 0.3 1.1 -2.67
Functional constipation / chronic idiopathic constipation 2.3 1.9 0.21
gallstone disease (gsd) 0.3 0.6 -1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.6 0.3 1
Generalized anxiety disorder 0.2 1.3 -5.5
Glioblastoma 0 0
Graves' disease 0.6 0.3 1
Halitosis 0.4 0 0
Hashimoto's thyroiditis 1.4 0.6 1.33
Hidradenitis Suppurativa 0.1 0 0
Histamine Issues,Mast Cell Issue, DAO Insufficiency 2.2 0.2 10
hypercholesterolemia (High Cholesterol) 0.4 0.8 -1
hyperglycemia 2 -2
Hyperlipidemia (High Blood Fats) 0.8 0.8
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 1.2 3.4 -1.83
Hypothyroidism 0.9 -0.9
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 2.5 -2.5
Inflammatory Bowel Disease 1.4 3.6 -1.57
Insomnia 0.4 0.6 -0.5
Intelligence 0.5 0.5
Intracranial aneurysms 0.5 0.5
Irritable Bowel Syndrome 3.3 2.6 0.27
Liver Cirrhosis 2 1.3 0.54
Long COVID 4.8 5.2 -0.08
Low bone mineral density 0.3 -0.3
Lung Cancer 0.8 1.1 -0.38
ME/CFS with IBS 0.7 1 -0.43
ME/CFS without IBS 1.2 0.8 0.5
Menopause 1.8 1.8
Metabolic Syndrome 3.5 5.7 -0.63
Mood Disorders 8.3 3.2 1.59
multiple chemical sensitivity [MCS] 0.5 0.1 4
Multiple Sclerosis 3.7 1.3 1.85
Multiple system atrophy (MSA) 1.4 0.6 1.33
Neuropathy (all types) 0.6 0.6
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.2 4.2 -20
NonCeliac Gluten Sensitivity 0.4 -0.4
Obesity 3.4 2.7 0.26
obsessive-compulsive disorder 2.4 2.2 0.09
Osteoarthritis 0.3 0.1 2
Osteoporosis 0.7 1.2 -0.71
pancreatic cancer 0.4 0.4
Parkinson's Disease 2 1 1
Polycystic ovary syndrome 0.6 1.5 -1.5
Postural orthostatic tachycardia syndrome 0.4 -0.4
Premenstrual dysphoric disorder 0.5 0.5
primary biliary cholangitis 0.1 0.5 -4
Psoriasis 1.5 1.2 0.25
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.2 1.7 0.29
Rosacea 0.5 0.1 4
Schizophrenia 4.7 0.7 5.71
scoliosis 0.6 -0.6
Sjögren syndrome 0.6 2.3 -2.83
Sleep Apnea 0.7 0.8 -0.14
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.6 -5
Stress / posttraumatic stress disorder 1.3 2.3 -0.77
Systemic Lupus Erythematosus 1.7 1.4 0.21
Tic Disorder 0.6 0.4 0.5
Tourette syndrome 0.4 0.3 0.33
Type 1 Diabetes 1.2 1.4 -0.17
Type 2 Diabetes 3.5 4.4 -0.26
Ulcerative colitis 0.9 3.2 -2.56
Unhealthy Ageing 2.4 1.3 0.85

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]